Panacea Life Sciences Holdings, Inc.
PLSH
$0.0539
$0.005912.29%
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.06M | 960.50K | 347.90K | 399.10K | 677.50K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.06M | 960.50K | 347.90K | 399.10K | 677.50K |
| Cost of Revenue | 1.86M | 1.94M | 1.49M | 1.33M | 1.71M |
| Gross Profit | -808.30K | -981.00K | -1.14M | -928.90K | -1.03M |
| SG&A Expenses | 249.00K | 787.10K | 276.70K | 145.20K | 257.40K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.11M | 2.73M | 1.76M | 1.47M | 1.97M |
| Operating Income | -1.06M | -1.77M | -1.41M | -1.07M | -1.29M |
| Income Before Tax | -1.45M | -2.21M | -2.15M | -1.86M | -1.79M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.45M | -2.21M | -2.15M | -1.86M | -1.79M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.45M | -2.21M | -2.15M | -1.86M | -1.79M |
| EBIT | -1.06M | -1.77M | -1.41M | -1.07M | -1.29M |
| EBITDA | -673.90K | -1.32M | -990.00K | -651.40K | -867.40K |
| EPS Basic | -0.09 | -0.13 | -0.13 | -0.11 | -0.12 |
| Normalized Basic EPS | -0.06 | -0.08 | -0.07 | -0.05 | -0.07 |
| EPS Diluted | -0.09 | -0.13 | -0.13 | -0.11 | -0.12 |
| Normalized Diluted EPS | -0.06 | -0.08 | -0.07 | -0.05 | -0.07 |
| Average Basic Shares Outstanding | 16.49M | 16.66M | 16.62M | 17.65M | 14.97M |
| Average Diluted Shares Outstanding | 16.49M | 16.66M | 16.62M | 17.65M | 14.97M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
